Cinven Completes Final Realisation of Medpace

International private equity firm Cinven has completed the final sell down of its remaining shares in Nasdaq-listed Medpace, realising its investment from the Fifth Cinven Fund. Medpace, a Cincinnati-based global contract research organisation (CRO), expanded internationally and grew its workforce substantially under Cinven's ownership before its August 2016 IPO and subsequent sell downs, with the final sell down achieved at a significant premium to the IPO price.